The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: A systematic review

M. Timmermans*, O. van der Hel, G. S. Sonke, K. K. Van de Vijver, M. A. van der Aa, R. F. Kruitwagen

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

95 Downloads (Pure)

Abstract

Introduction. The ability to minimize residual disease during primary cytoreductive surgery is the strongest predictor for improved overall survival in advanced ovarian cancer. But while the probability to achieve a macroscopic complete resection increases if surgery is preceded by neoadjuvant chemotherapy (NACT), survival rates after NACT are similar to those observed after primary surgery. This may suggest that the prognostic effect of residual disease is altered after NACT. More specifically, randomized data suggest that there is no difference between optimal (0.1-1 cm) and suboptimal (>1 cm) cytoreductive surgery after NACT. Therefore, the aim of the current review is to establish the prognostic effect of the amount of residual disease after interval cytoreductive surgery (ICS) on overall survival.

Methods. Potential articles for inclusion in the current review were systematically searched through Medline, Embase and Cochrane in September 2017. Median overall survival (mOS) was summarized by the outcome of ICS per study. In addition, mOS was summarized for all studies together stratified by the outcome of ICS, based on the principle of a weighted average.

Results. In total, 3677 unique manuscripts were individually screened on title and abstract, which resulted in 11 individual studies that comprised a total of 2178 patients. MOS was 41 months for patients with no residual disease (range 33-54 months), 27 months for patients with 0.1-1 cm of residual disease (range 19-38 months) and 21 months with >1 cm of residual disease (range 14-27 months). Six studies showed significant differences between optimal and suboptimal ICS, while five studies showed no differences.

Conclusion. The summary of the currently available literature showed that after NACT, patients with optimal cytoreductive surgery experience lengthened survival compared to patients with suboptimal cytoreductive surgery. Patients with no macroscopic residual disease have, however, the most favorable survival outcomes, similar to what is seen after primary cytoreductive surgery. (C) 2019 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)445-451
Number of pages7
JournalGynecologic Oncology
Volume153
Issue number2
DOIs
Publication statusPublished - May 2019

Keywords

  • Neoadjuvant chemotherapy
  • Interval cytoreductive surgery
  • Outcome of surgery
  • Overall survival
  • ADVANCED-STAGE OVARIAN
  • PRIMARY CYTOREDUCTIVE SURGERY
  • INTERVAL DEBULKING SURGERY
  • GYNECOLOGIC ONCOLOGISTS
  • SURGICAL CYTOREDUCTION
  • AGGRESSIVE SURGERY
  • PERITONEAL CANCER
  • IV OVARIAN
  • SURVIVAL
  • CARCINOMA

Fingerprint

Dive into the research topics of 'The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: A systematic review'. Together they form a unique fingerprint.

Cite this